December 11, 2016 12:42 AM ET

Pharmaceuticals

Company Overview of Ocular Therapeutix, Inc.

Company Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. The company’s lead product includes DEXTENZA, which is in Phase III clinical trial for the treatment of post-surgical ocular inflammation and pain during cataract surgery, as well as for the treatment of allergic conjunctivitis; and in Phase II clinical trial for the treatment of inflammatory dry eye disease. It is also developing OTX-TP, which h...

34 Crosby Drive

Suite 105

Bedford, MA 01730

United States

Founded in 2006

94 Employees

Phone:

781-357-4000

Fax:

781-357-4001

Key Executives for Ocular Therapeutix, Inc.

Founder, Chairman, Chief Executive Officer and President
Age: 49
Total Annual Compensation: $723.7K
Chief Financial Officer and Chief Accounting Officer
Age: 60
Total Annual Compensation: $428.6K
Chief Operating Officer
Age: 57
Total Annual Compensation: $499.0K
Compensation as of Fiscal Year 2015.

Ocular Therapeutix, Inc. Key Developments

Ocular Therapeutix, Inc. - Special Call

To discuss the topline results of the recently completed Phase 3 clinical trial of DEXTENZA for the treatment of ocular inflammation and pain following ophthalmic surgery

Ocular Therapeutix™ Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA™

Ocular Therapeutix, Inc. announced positive topline results from its phase 3 clinical trial of DEXTENZA™ (dexamethasone insert) 0.4 mg, for the treatment of post-surgical ocular inflammation and pain. DEXTENZA is a product candidate administered by a physician as a bioresorbable intracanalicular insert and designed for drug release to the ocular surface for up to 30 days. The trial successfully met its two primary efficacy endpoints for inflammation and pain, achieving statistically significant differences between the treatment group and the placebo group for the absence of inflammatory cells on day 14 and the absence of pain on day 8, respectively. 52.3%% of patients treated with DEXTENZA showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14, compared to 31.1% of those receiving the placebo vehicle control punctum plug (p< 0.0001). 79.6% of patients treated with DEXTENZA reported absence of pain in the study eye on day 8, compared to 61.3% of those receiving the placebo vehicle control punctum plug (p< 0.0001).

Ocular Therapeutix, Inc. Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-30-2016 03:30 PM

Ocular Therapeutix, Inc. Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-30-2016 03:30 PM. Venue: The Lotte New York Palace, 50th St. and Madison Avenue, New York, New York, United States. Speakers: Amarpreet Sawhney, Founder, Chairman, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ocular Therapeutix, Inc., please visit www.ocutx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.